Skip to main content
Sinopharm Tech Holdings Limited logo

Sinopharm Tech Holdings Limited — Investor Relations & Filings

Ticker · 8156 ISIN · KYG2159V1418 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country HK Hong Kong
Listing HKEX 8156

About Sinopharm Tech Holdings Limited

http://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Limited is an investment holding company primarily engaged in the big health industry and pharmaceutical supply chain business. The company focuses on the trading and distribution of medical and related products, including Chinese patent medicines and health products, targeting the market in the PRC. It develops its supply chain operations using "Internet Plus" services, leveraging technology to provide value-added services to industry operators and product suppliers. The Group is also integrating AI analytics to enhance its operations within the healthcare sector.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Sinopharm Tech Holdings Limited regarding the date of a board meeting scheduled to approve the interim results for the six months ended 31 December 2021 and consider dividend payment. The text explicitly states it is an announcement of the meeting date and the purpose of the meeting, not the interim report itself. The document length is short (2407 characters) and it does not contain any financial data or detailed results. It is clearly a notice about the timing of a board meeting related to financial results, which fits the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories. It is not the interim report (IR) itself, nor a report publication announcement (RPA) since it does not mention report publication or attachment. Therefore, the correct classification is Regulatory Filings (RNS).
2022-01-28 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2021
Regulatory Filings Classification · 95% confidence The document is titled as a "SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2021" and provides additional information regarding impairment loss on goodwill and share award scheme related to the Annual Report. It references specific notes and pages of the Annual Report and clarifies that the additional information does not affect other information contained in the Annual Report. The document is not the Annual Report itself but a supplemental announcement providing further details related to the Annual Report. It is longer than 5,000 characters and contains substantive information, but it is clearly an announcement supplementing the Annual Report rather than the full report. Therefore, it fits best under Regulatory Filings (RNS) as a supplemental announcement related to the Annual Report, not the Annual Report itself (10-K).
2022-01-18 English
INSIDE INFORMATION - UPDATE ON THE CONVERTIBLE BONDS
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sinopharm Tech Holdings Limited regarding the status of its Convertible Bonds, including details about maturity, default events, and potential negotiations for renewal or extension. It references regulatory rules (GEM Listing Rules) and provides an update on financing instruments but does not contain financial statements or detailed financial analysis. The document is relatively short (5117 characters) and serves as an update on capital structure and financing activities rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-01-18 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report concerning movements in securities, specifically focusing on authorized and issued shares, share options, convertible bonds, and other share capital changes for Sinopharm Tech Holdings Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, particularly Chapter 19B. The document includes detailed tables of share capital movements, share options, convertible bonds, and confirmations by the company secretary. It is a regulatory submission related to share capital and securities movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management analysis but is a formal regulatory filing reporting share capital changes and confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-06 English
VOLUNTARY ANNOUNCEMENT - THE CUMULATIVE QUANTITY OF THE COMMERCIAL CONTRACTS EXCEEDED 25 MILLION UNITS PER YEAR ON AVERAGE OF ANTI-COUNTERFEITING PRODUCTS - ANTI-COUNTERFEITING BUSINESS PROGRESS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Sinopharm Tech Holdings Limited regarding the progress and business development of their anti-counterfeiting products. It does not contain financial statements, regulatory certifications, voting results, or any detailed financial or management reports. The text is an update on business progress and market development, typical of a voluntary business update announcement. It is not an annual or interim report, earnings release, or any regulatory filing. The document is relatively short (6355 characters) and serves to inform shareholders and investors about business progress rather than financial results or governance matters. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2021-12-20 English
VOLUNTARY ANNOUNCEMENT EXPANSION OF SALES CHANNEL IN GUIZHOU PROVINCE FOR ANTI-COUNTERFEITING BUSINESS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Sinopharm Tech Holdings Limited regarding the expansion of sales channels for their anti-counterfeiting business in Guizhou Province. It details a strategic cooperation agreement and business development activities. There are no financial statements, regulatory certifications, voting results, or management changes reported. The document is informational about business development and does not fit into financial reports, governance, or regulatory filings categories. It is not a report publication announcement since it contains substantive business content rather than just announcing a report release. The best fitting category is a general regulatory announcement about business updates, which falls under Regulatory Filings (RNS).
2021-12-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.